Neuroendocrine Tumor
Oncology
5
Pipeline Programs
6
Companies
5
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 6 programs with unclassified modality
Competitive Landscape
6 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
IpsenCabozantinib 40 mg
AmgenAMG 479
XencorXmAb18087
NovartisLutetium-177 DOTATATE
NovartisMagnetic Tracking System
Clinical Trials (5)
Total enrollment: 197 patients across 5 trials
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
Start: Oct 2020Est. completion: Dec 202393 patients
Phase 2Completed
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Start: Mar 2010Est. completion: Jan 201760 patients
Phase 2Completed
A Study of XmAb®18087 in Subjects With NET and GIST
Start: Jan 2018Est. completion: Oct 2021
Phase 1Completed
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Start: Sep 2021Est. completion: Jan 202231 patients
N/ACompleted
Gastrointestinal Motility in Patients With Neuroendocrine Tumors
Start: Sep 2008Est. completion: May 201013 patients
N/ACompleted
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
4h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
4h ago
Office Administrator
SystImmune
4h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
4h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
4h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
4h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
6 companies competing in this space